Finished-product evidence
VigRX Plus Clinical Research
A published trial evaluated a VigRX Plus multi-herb formula in men with mild-to-moderate or moderate erectile dysfunction. It was a randomized, double-blind, placebo-controlled, parallel-group, multicenter study.
The trial is more directly relevant than research on isolated ingredients because participants received a finished VigRX Plus formula. However, it was a modest, 12-week study, was funded by the product company, and used a formula and daily tablet count that should not be assumed identical to today's product. The main outcome was the erectile-function domain of the International Index of Erectile Function (IIEF-EF), a validated questionnaire—not a direct measurement of penile size or a guarantee of satisfaction.
- Study title
- Evaluation of a multi-herb supplement for erectile dysfunction: a randomized double-blind, placebo-controlled study
- Publication
- 2012, BMC Complementary and Alternative Medicine (now BMC Complementary Medicine and Therapies)
- Design
- Randomized, double-blind, placebo-controlled, parallel-group, multicenter
- Participants
- 108 screened; 78 enrolled; 75 completed
- Age
- 25–50 years eligible; enrolled group ranges reported as 25–48 and 25–44
- Participant characteristics
- Men with mild-to-moderate or moderate erectile dysfunction by IIEF-EF criteria
- Duration
- 12 weeks
- Study dosage
- Two tablets twice daily (four daily)
- Comparator
- Matching placebo
- Main outcome
- Change in IIEF erectile-function domain score
- Trial registration
- CTRI/2009/091/000099
- Reported adverse events
- No serious adverse events reported; the paper describes comparable tolerability findings, but the sample was too small to detect rare harms
- Funding
- Leading Edge Herbals funded trial medications, study requirements and publication charges; authors stated the funder did not influence scientific conduct or manuscript preparation
- Key limitations
- Small sample, 12-week duration, company funding, questionnaire outcomes, selected participant group and uncertain equivalence to the current marketed formula
How to interpret the reported result
The paper reported a statistically significant improvement in IIEF-EF scores compared with placebo at 12 weeks. That finding applies to the measured questionnaire outcome, at the studied dose, in the enrolled population. It does not establish permanent enhancement, penile enlargement, universal response or an identical result from today's serving.
Why percentage claims need context
Marketing percentages can refer to within-group changes from baseline rather than an absolute difference versus placebo. Without the outcome, denominator, comparison and time point, a percentage can mislead. This page therefore emphasizes the study design and measured outcome instead of repeating isolated promotional percentages.